Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 2,940 Shares

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 2,940 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the sale, the director now directly owns 18,173 shares of the company’s stock, valued at $965,531.49. The trade was a 13.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40.

Twist Bioscience Trading Down 5.0 %

TWST stock traded down $2.43 during mid-day trading on Tuesday, hitting $46.20. 1,012,959 shares of the company were exchanged, compared to its average volume of 834,298. The business has a fifty day simple moving average of $48.87 and a 200-day simple moving average of $46.07. The company has a quick ratio of 4.54, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The firm has a market capitalization of $2.76 billion, a P/E ratio of -13.67 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the firm posted ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, Scotiabank upped their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $53.80.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience in the third quarter worth approximately $43,992,000. State Street Corp lifted its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Jennison Associates LLC increased its holdings in shares of Twist Bioscience by 80.2% in the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after acquiring an additional 302,884 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of Twist Bioscience by 63.5% in the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock valued at $35,148,000 after acquiring an additional 293,751 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.